Dosing regimens and main adverse events of bisphosphonates

[1] Bauss Frieder, 1994, Drugs of the Future, V19, P13

[2] TREATMENT OF TUMOR-INDUCED HYPERCALCEMIA WITH THE BISPHOSPHONATE PAMIDRONATE - DOSE-RESPONSE RELATIONSHIP AND INFLUENCE OF TUMOR TYPE [J]. ANNALS OF ONCOLOGY, 1994, 5 (04) : 359 - 363

[3] A dose-finding study of zoledronate in hypercalcemic cancer patients [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (09) : 1557 - 1561

[4] Current use of bisphosphonates in oncology [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3890 - 3899

[5] Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (03) : 408 - 412

[6] Body JJ, 1997, CANCER, V80, P1699, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.3.CO

[7] 2-A

[8] URINARY PYRIDINIUM CROSS-LINKS AS MARKERS OF BONE-RESORPTION IN TUMOR-ASSOCIATED HYPERCALCEMIA [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) : 471 - 475

[9] Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease [J]. ANNALS OF ONCOLOGY, 1999, 10 (03) : 311 - 316

[10] Esophagitis associated with the use of alendronate [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1016 - 1021

[1] Bauss Frieder, 1994, Drugs of the Future, V19, P13

[2] TREATMENT OF TUMOR-INDUCED HYPERCALCEMIA WITH THE BISPHOSPHONATE PAMIDRONATE - DOSE-RESPONSE RELATIONSHIP AND INFLUENCE OF TUMOR TYPE [J]. ANNALS OF ONCOLOGY, 1994, 5 (04) : 359 - 363

[3] A dose-finding study of zoledronate in hypercalcemic cancer patients [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (09) : 1557 - 1561

[4] Current use of bisphosphonates in oncology [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3890 - 3899

[5] Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (03) : 408 - 412

[6] Body JJ, 1997, CANCER, V80, P1699, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.3.CO

[7] 2-A

[8] URINARY PYRIDINIUM CROSS-LINKS AS MARKERS OF BONE-RESORPTION IN TUMOR-ASSOCIATED HYPERCALCEMIA [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) : 471 - 475

[9] Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease [J]. ANNALS OF ONCOLOGY, 1999, 10 (03) : 311 - 316

[10] Esophagitis associated with the use of alendronate [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1016 - 1021